These JAK1 frameshift mutations have previously been described as recurrent mutations and non-functional mutations, especially in dMMR/MSI-H tumours and have been associated with resistance to ICI if complete loss of function occurs [9, 40, 48–51]. This evidence concerns the gene JAK1 and neoplasm.